
Understanding and Reducing Your Risk for AMD
February is Age-Related Macular Degeneration Awareness Month. A serious degenerative eye disease that can cause irreversible vision loss or blindness if left untreated, AMD is the most common reason patients are referred
read more
Shining a Spotlight on Age-related Macular Degeneration (AMD)
February is national age-related macular degeneration (AMD) and low vision awareness month. Low vision is a visual impairment that cannot be corrected by standard eyeglasses, contact lenses, medication, or surgery. AMD, a deterioration, or
read more
Texas Retina Associates First in U.S. to Dose a Patient in the Phase 2 SIGLEC Trial
On June 1, 2023, Ashkan Abbey, MD, dosed the first patient in the Phase II SIGLEC Trial, a clinical study evaluating AVD-104, a potential new treatment for geographic atrophy (GA) from age-related
read more
Meet Our Fort Worth Clinical Research Coordinators
Lori Hastings and Tina Bell serve as the clinical research coordinators for our Fort Worth office, managing the enrollment and participation of patients in our clinical trials. These studies explore promising new
read more